Making a comeback after a negative experience with the US Food and Drug Administration
This article was originally published in RAJ Devices
Executive Summary
Negative feedback from the US Food and Drug Administration does not necessarily mean disaster. Glenn Neuman tells companies how to get back on their feet after a rejection.
You may also be interested in...
Clinica 100: What lies ahead for US device regulation
The jury is still out as to how the US regulatory system is going to evolve in the long term, but change it will. As the FDA gathers feedback on the IOM's damning report on the 510(k) system and the recommended changes, Glenn Neuman, director of scientific affairs at New World Regulatory Solutions*, details what to expect in the short term
Complaint handling: a window into the soul of your quality system
An inadequate complaint handling system is a frequent shortcoming highlighted in US Food and Drug Administration warning letters. Glenn Neuman of New World Regulatory Solutions gives some pointers on how to strengthen your quality system and overcome one of the most frequent stumbling blocks for medtech companies.
Complaint handling: a window into the soul of your quality system
An inadequate complaint handling system is a frequent shortcoming highlighted in US Food and Drug Administration warning letters. Glenn Neuman of New World Regulatory Solutions gives some pointers on how to strengthen your quality system and overcome one of the most frequent stumbling blocks for medtech companies.